Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients

Area of Science:

• Neurology
• Molecular Biology
• Genetics

Background:

• Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder.
• Myostatin pathway dysregulation is implicated in SMA.
• Current SMA treatments focus on increasing survival motor neuron protein, but myostatin's role requires further investigation.

Purpose of the Study:

• To investigate the correlation between myostatin and follistatin levels with disease severity in SMA patients.
• To explore the impact of disease-modifying treatments (DMTs), specifically nusinersen, on myostatin and follistatin levels in SMA.

Main Methods:

• Retrospective analysis of clinical data from 25 Belgian SMA patients (SMA1, SMA2, SMA3) treated with nusinersen.
• Collection of myostatin and follistatin levels at baseline and multiple time points (2, 6, 10, 18, 30 months) post-treatment.
• Correlation analysis between biomarker levels, patient characteristics (age, weight, SMA type), and motor function scores (MFM32, HFMSE, 6MWT).

Main Results:

• Pre-treatment myostatin levels showed significant correlations with patient age, weight, SMA type, and motor function.
• Post-nusinersen treatment, myostatin levels correlated with certain motor function scores (MFM32, HFMSE, 6MWT).
• Nusinersen treatment did not demonstrate a major effect on myostatin or follistatin levels over the observed 30-month period.

Conclusions:

• Myostatin and follistatin levels are associated with SMA disease characteristics and motor function.
• Current disease-modifying therapies like nusinersen may not significantly alter myostatin or follistatin levels in SMA patients.
• Further research is warranted to understand the interplay between DMTs, myostatin pathway, and potential therapeutic strategies for SMA, including patient selection for myostatin inhibitor trials.